Boule Diagnostics wins strategic instruments procurement

Boule Diagnostics AB has won the procurement of instruments for blood cell counting in primary care in Östergötland. This contract was made by the County Council of Östergötland and includes 35 of Boules recently introduced generation of instruments; Swelab Alpha Plus. The installation will take place during the second quarter of 2015.

“We have continued to increase instrument sales throughout 2014, but this order stands out both in terms of strategic importance and contracting organization. This contract is one of the largest in our segment on our home market. Furthermore, the County Council of Östergötland has high quality standards, which means we additionally get a good sparring partner in our ongoing efforts to continually ensure the highest quality. It is very gratifying that we have won the contract in competition with our major international competitors. Swelab Alpha Plus has just been launched and is the result of extensive development. Along with new instruments in the Medonic Series, they represent the next generation of instruments and will be introduced successively in the rest of the world. The agreement also includes seven years of sales of our consumables and service revenues during most of the period of the agreement”, says Ernst Westman, President and CEO, Boule Diagnostics AB.

For more information, please contact:
Ernst Westman, President and CEO, Boule Diagnostics AB, phone +46 708-60 88 63

The information in this press release is such that Boule Diagnostics AB must disclose it in accordance with the Securities Market Act and/or the Financial Instruments Trading. The information was submitted for publication at 8:30 am (CET), January 8, 2015.


About Boule Diagnostics AB
Boule Diagnostics AB is a fast-growing diagnostics company, developing and manufacturing systems and consumables for hematology diagnostics for the public healthcare providers worldwide. The company is primarily focused on small and medium-sized hospitals, clinics and laboratories in outpatient care as well as other diagnostics companies in both human and veterinary haematology. The group is comprised of operating subsidiaries in Sweden, the US and China. The Boule Diagnostics share is, since 2011, traded on NASDAQ OMX Nordic.

Press release (PDF)

  • Subscribe to our news